Valuation: Cerus Corporation

Market Cap 572M 496M 465M 424M 798M 54.62B 811M 5.48B 2.14B 27.34B 2.15B 2.1B 91.21B P/E 2026 *
-65.5x
P/E 2027 * -426x
Enterprise Value 572M 496M 465M 424M 798M 54.62B 811M 5.48B 2.14B 27.34B 2.15B 2.1B 91.21B EV / Sales 2026 *
2.36x
EV / Sales 2027 * 2.13x
Free-Float
96.33%
Yield 2026 *
-
Yield 2027 * -
1 day+4.80%
1 week+22.41%
Current month+32.09%
1 month-8.09%
3 months+9.23%
6 months+26.79%
Current year+37.86%
1 week 2.29
Extreme 2.29
2.9
1 month 2.06
Extreme 2.06
3.29
Current year 1.62
Extreme 1.62
3.47
1 year 1.15
Extreme 1.15
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
6/30/26 Free

Chief Financial Officer

-97,276 0.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+4.80%+22.41%+113.53%+45.64% 546M
-1.76%+1.08%-9.99%+20.91% 133B
+1.10%+0.68%-18.29%-1.25% 12.42B
+1.51%+10.80%+106.40%+154.67% 11B
-0.62%+0.71%-44.45%-67.34% 4.65B
-0.40%+4.55%-26.83%+43.11% 2.75B
-0.14%-1.17%-33.38%-76.03% 1.68B
+0.43%+2.71%-22.25%-11.67% 1.68B
+0.48%+2.30%-33.07%-33.76% 1.66B
Average +0.60%+3.53%+3.52%+8.25% 18.84B
Weighted average by Cap. -1.20%+1.62%-4.45%+24.16%

Financials

2026 *2027 *
Net sales 243M 210M 197M 180M 338M 23.15B 344M 2.32B 906M 11.59B 911M 891M 38.66B 268M 233M 218M 199M 374M 25.61B 380M 2.57B 1B 12.82B 1.01B 986M 42.77B
Net income -8.4M -7.28M -6.83M -6.23M -11.72M -802M -11.9M -80.41M -31.39M -402M -31.55M -30.87M -1.34B -1.45M -1.25M -1.17M -1.07M -2.02M -138M -2.05M -13.83M -5.4M -69.08M -5.43M -5.31M -230M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-08-13 US$2.840 +4.80% 2,810,626
26-08-12 US$2.710 +5.65% 2,719,910
26-08-11 US$2.565 +1.79% 3,526,729
26-08-10 US$2.520 +7.23% 2,726,409
26-08-07 US$2.350 +1.29% 3,484,714
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.840USD
Average target price
4.667USD
Spread / Average Target
+64.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock